NeuroRPM to provide AI monitoring for Annovis Parkinson’s trial
NeuroRPM’s FDA-cleared wearable platform is being used to monitor digital biomarkers in the open-label ANVS-25002 trial in Parkinson’s disease. The study is expected to enroll approximately 500 participants at multiple clinical sites, and eligible participants may join NeuroRPM monitoring to…











